936 related articles for article (PubMed ID: 18391612)
21. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy.
Tina Shih YC; Xu Y; Elting LS
Cancer; 2007 Aug; 110(3):678-85. PubMed ID: 17567835
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.
Navari RM
Drugs; 2009; 69(5):515-33. PubMed ID: 19368415
[TBL] [Abstract][Full Text] [Related]
23. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use.
Wickham R
J Support Oncol; 2010; 8(2 Suppl 1):10-5. PubMed ID: 20629453
[TBL] [Abstract][Full Text] [Related]
24. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
Massaro AM; Lenz KL
Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
[TBL] [Abstract][Full Text] [Related]
25. Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
Navari RM
Expert Opin Pharmacother; 2009 Mar; 10(4):629-44. PubMed ID: 19284365
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Schwartzberg LS
Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
[TBL] [Abstract][Full Text] [Related]
27. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
28. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
29. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
30. Anti-emetic therapy in cancer chemotherapy: current status.
Herrstedt J; Dombernowsky P
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
[TBL] [Abstract][Full Text] [Related]
31. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
Sarcev T; Secen N; Zaric B; Milovancev A
J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
[TBL] [Abstract][Full Text] [Related]
32. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.
Antonarakis ES; Hain RD
Arch Dis Child; 2004 Sep; 89(9):877-80. PubMed ID: 15321871
[TBL] [Abstract][Full Text] [Related]
33. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).
Roila F; Warr D; Aapro M; Clark-Snow RA; Einhorn L; Gralla RJ; Herrstedt J; Saito M; Tonato M
Support Care Cancer; 2011 Mar; 19 Suppl 1():S57-62. PubMed ID: 21132332
[TBL] [Abstract][Full Text] [Related]
34. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
35. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
Jordan K; Roila F; Molassiotis A; Maranzano E; Clark-Snow RA; Feyer P;
Support Care Cancer; 2011 Mar; 19 Suppl 1():S37-42. PubMed ID: 20824481
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy-induced nausea and vomiting.
Hesketh PJ
N Engl J Med; 2008 Jun; 358(23):2482-94. PubMed ID: 18525044
[No Abstract] [Full Text] [Related]
37. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
[TBL] [Abstract][Full Text] [Related]
38. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes.
Hawkins R; Grunberg S
Clin J Oncol Nurs; 2009 Feb; 13(1):54-64. PubMed ID: 19193549
[TBL] [Abstract][Full Text] [Related]
40. [Chemotherapy induced emesis: pathophysiology and prevention].
Mailliez A; Bonneterre J
Bull Cancer; 2010 Feb; 97(2):233-43. PubMed ID: 20051348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]